Dr. Reddy's Laboratories Limited (BOM:500124)
India flag India · Delayed Price · Currency is INR
1,259.25
+6.70 (0.53%)
At close: Aug 14, 2025

Dr. Reddy's Laboratories Company Description

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.

The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products.

This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements.

The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations.

The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management.

Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Dr. Reddy's Laboratories Limited
CountryIndia
Founded1984
IndustryPharmaceutical Preparations
Employees27,811
CEOErez Israeli

Contact Details

Address:
8-2-337, Road No. 3
Hyderabad, 500034
India
Phone91 40 4900 2900
Websitedrreddys.com

Stock Details

Ticker Symbol500124
ExchangeBombay Stock Exchange
Fiscal YearApril - March
Reporting CurrencyINR
SIC Code2834

Key Executives

NamePosition
Erez IsraeliChief Executive Officer
Mannam VenkatanarasimhamChief Financial Officer
Richa PeriwalHead of Investor Relations